Renesis (Roxadustat) is a the first-in-class, oral tablet that promotes erythropoiesis through the endogenous production of erythropoietin (EPO) near physiological range. Upon administration, roxadustat binds to and inhibits HIF-PH (Prolyl Hyroxylase) , an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin Production.
It also upregulates the distribution, metabolism and absorption of iron within the body as well as downregulates hepcidin which is responsible for improper intracellular iron transportation.
Therefore, Renesis (Roxadustat) can induce endogenous production of mature HB plump with iron.
Renesis (Roxadustat) is indicated for treatment of adult patients with systematic anemia and functional iron deficiency anaemia associated with chronic kidney disease (CKD), Chemotherapy induced anemia and chronic disease induced anemia. Reneis (Roxadust) also improves hypo responsiveness of ESA in CKD patients.
|Generic Name||Roxadustat INN|
|Available Pack Size||3’s|
|Available Strength||20 mg, 50 mg, 70mg & 100 mg|